• Abciximab ReoPro 1994 chimeric inhibition of glycoprotein IIb/IIIa Cardiovascular disease
• Infliximab Remicade 1998 chimeric I inhibition of TNF-a Inflammatory diseases Adalimumab Humira 2002 human inhibition of TNF-a signalling Inflammatory diseases
• Natalizumab Tysabri 2006 humanized T cell VLA4 receptor Inflammatory diseases . (esp autoimmune-related multiple sclerosis therapy)
• Omalizumab Xolair 2004 humanized Ig E Inflammatory diseases . (mainly allergy-related asthma therapy)
• Eculizumab Soliris 2007 humanized complement C5 Inflammatory diseases . (PNH)
• Efalizumab Raptiva 2002 humanized CD11a Inflammatory diseases . (psoriasis)
• Alemtuzumab Campath 2001 humanized CD52 CLL Gemtuzumab Mylotarg 2000 humanized CD33 AML . (with calicheamicin)
• Ri - tuximab Rituxan, Mabthera 1997 chimeric CD20 NHL Ibritumomab tiuxetan Zevalin 2002murine CD20 NHL (with yttrium-90 or indium-111) Tostumomab Bexxar 2003 murine CD20 NHL
• Daclizumab Zenapax 1997 humanized IL-2 receptor Transplant rejection Basiliximab Simulect 1998 chimeric IL-2 receptor Transplant rejection MuromonabOrthoclone OKT3 1986 murine CD3 Receptor Transplant rejection
• Bevaciz umab Avastin 2004 humanized vascular endothelial growth factor Colorectal cancer Panitumumab Vectibix 2006human epidermal growth factor receptor Colorectal cancer Cetuximab Erbitux 2004 chimeric epidermal growth factor receptor Colorectal cancer
• Ranibizumab Lucentis 2006 humanized vascular endothelial growth factor Macular degeneration
• Palivizumab Synagis 1998 humanized epitope of F protein of RSV Viral infection (espRSV)
• Trastuzumab Herceptin 1998 humanized ErbB2 Breast cancer
-mab suffix monoclonal antibody.
if immediately before mab----u--its humane derived
. ---mo--its murine
. ----i----its chimeric.
• Infliximab Remicade 1998 chimeric I inhibition of TNF-a Inflammatory diseases Adalimumab Humira 2002 human inhibition of TNF-a signalling Inflammatory diseases
• Natalizumab Tysabri 2006 humanized T cell VLA4 receptor Inflammatory diseases . (esp autoimmune-related multiple sclerosis therapy)
• Omalizumab Xolair 2004 humanized Ig E Inflammatory diseases . (mainly allergy-related asthma therapy)
• Eculizumab Soliris 2007 humanized complement C5 Inflammatory diseases . (PNH)
• Efalizumab Raptiva 2002 humanized CD11a Inflammatory diseases . (psoriasis)
• Alemtuzumab Campath 2001 humanized CD52 CLL Gemtuzumab Mylotarg 2000 humanized CD33 AML . (with calicheamicin)
• Ri - tuximab Rituxan, Mabthera 1997 chimeric CD20 NHL Ibritumomab tiuxetan Zevalin 2002murine CD20 NHL (with yttrium-90 or indium-111) Tostumomab Bexxar 2003 murine CD20 NHL
• Daclizumab Zenapax 1997 humanized IL-2 receptor Transplant rejection Basiliximab Simulect 1998 chimeric IL-2 receptor Transplant rejection MuromonabOrthoclone OKT3 1986 murine CD3 Receptor Transplant rejection
• Bevaciz umab Avastin 2004 humanized vascular endothelial growth factor Colorectal cancer Panitumumab Vectibix 2006human epidermal growth factor receptor Colorectal cancer Cetuximab Erbitux 2004 chimeric epidermal growth factor receptor Colorectal cancer
• Ranibizumab Lucentis 2006 humanized vascular endothelial growth factor Macular degeneration
• Palivizumab Synagis 1998 humanized epitope of F protein of RSV Viral infection (espRSV)
• Trastuzumab Herceptin 1998 humanized ErbB2 Breast cancer
-mab suffix monoclonal antibody.
if immediately before mab----u--its humane derived
. ---mo--its murine
. ----i----its chimeric.